Compare · NVO vs PYPD
NVO vs PYPD
Side-by-side comparison of Novo Nordisk A/S (NVO) and PolyPid Ltd. (PYPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PYPD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 2610.6x PYPD ($84.4M).
- Over the past year, NVO is down 34.2% and PYPD is up 81.9% - PYPD leads by 116.1 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for PYPD).
- NVO has more recent analyst coverage (25 ratings vs 6 for PYPD).
- Company
- Novo Nordisk A/S
- PolyPid Ltd.
- Price
- $41.18+6.93%
- $4.61-1.28%
- Market cap
- $220.35B
- $84.4M
- 1M return
- +13.32%
- +5.98%
- 1Y return
- -34.24%
- +81.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest PYPD
- PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
- SEC Form 3 filed by new insider Jacobovitz Yitzchak Shlomo
- SEC Form 3 filed by new insider Stein Robert Benjamin
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
- SEC Form 3 filed by new insider Warshavsky Ori
- SEC Form 3 filed by new insider Dror-Darwish Nir
- SEC Form 3 filed by new insider Missulawin Jonathan
- SEC Form 3 filed by new insider Barenholz Yechezkel
- SEC Form 3 filed by new insider Benamram Joseph